Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors

被引：0
|
作者：
Wahlroos, Sara
Teng, Christina
Tran, Ben
Voskoboynik, Mark
Gan, Hui Kong
Spencer, Andrew
Kudva, Anupa
Song, Ming
Lynch, Kevin
Yu, Zhinuan
Desai, Jayesh
Lemech, Charlotte Rose
Lifehouse, Chris O'Brien
机构：
[1] Scientia Clin Res, Randwick, NSW, Australia
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Monash Univ, Cent Clin Sch, Dept Med Oncol, Alfred Hosp, Melbourne, Australia
[4] Austin Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[5] Alfred, Melbourne, Vic, Australia
[6] Antengene Therapeut Ltd, Melbourne, Vic, Australia
[7] Antengene Therapeut Ltd, Shanghai, Peoples R China
[8] Antengene Therapeut Ltd, Madison, NJ USA
[9] Scientia Clin Res Ltd, Randwick, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15114
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: Dose-escalation results of monotherapy
    Yu, Xianjun
    Zhang, Jian
    Sun, Yuping
    Deng, Yanhong
    Guo, Shuangshuang
    Hong, Wei
    Shi, Si
    Liu, Rujiao
    Gao, Shuiping
    Dang, Qi
    Zhang, Jianwei
    Su, Weiguo
    Shi, Michael
    Fan, Songhua
    Zhang, Bo
    Pan, Beiqing
    Jia, Xiaoyun
    Wang, Jian
    Zhong, Chen
    Ma, Luguang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
    Yu, X.
    Zhang, J.
    Liu, R.
    Deng, Y.
    Cai, Y.
    Sun, Y.
    Dang, Q.
    Hong, W.
    Song, Z.
    Guo, S.
    Gao, S.
    Su, W.
    Shi, M.
    Fan, S.
    Zhang, B.
    Pan, B.
    Ren, Y.
    Wang, J.
    Zhong, C.
    Ma, L.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497
  • [3] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Infante, Jeffrey R.
    Mendelson, David S.
    Burris, Howard A., III
    Bendell, Johanna C.
    Tolcher, Anthony W.
    Gordon, Michael S.
    Gillenwater, Heidi H.
    Arastu-Kapur, Shirin
    Wong, Hansen L.
    Papadopoulos, Kyriakos P.
    [J]. INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224
  • [4] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Jeffrey R. Infante
    David S. Mendelson
    Howard A. Burris
    Johanna C. Bendell
    Anthony W. Tolcher
    Michael S. Gordon
    Heidi H. Gillenwater
    Shirin Arastu-Kapur
    Hansen L. Wong
    Kyriakos P. Papadopoulos
    [J]. Investigational New Drugs, 2016, 34 : 216 - 224
  • [5] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Mathiot, Laurent
    Combarel, David
    Cagnat, Justin
    Delahousse, Julia
    Ouali, Kaissa
    Marabelle, Aurelien
    Loriot, Yohann
    Ponce, Santiago
    Champiat, Stephane
    Broutin, Sophie
    Danlos, Francois-Xavier
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [6] A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
    Varga, A.
    Soria, J. C.
    Hollebecque, A.
    LoRusso, P.
    Vaishampayan, U.
    Okrah, K.
    Huang, S. M. A.
    Murray, E.
    Sanabria-Bohorquez, S.
    Tagen, M.
    Dokainish, H.
    Mueller, L.
    Burris, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S11 - S11
  • [7] A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
    Varga, Andrea
    Soria, Jean-Charles
    Hollebecque, Antoine
    LoRusso, Patricia
    Bendell, Johanna
    Huang, Shih-Min A.
    Wagle, Marie-Claire
    Okrah, Kwame
    Liu, Lichuan
    Murray, Elaine
    Sanabria-Bohorquez, Sandra M.
    Tagen, Michael
    Dokainish, Hatem
    Mueller, Lars
    Burris, Howard
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1229 - 1236
  • [8] First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
    Sullivan, Ryan J.
    Infante, Jeffrey R.
    Janku, Filip
    Wong, Deborah Jean Lee
    Sosman, Jeffrey A.
    Keedy, Vicki
    Patel, Manish R.
    Shapiro, Geoffrey I.
    Mier, James W.
    Tolcher, Anthony W.
    Wang-Gillam, Andrea
    Sznol, Mario
    Flaherty, Keith
    Buchbinder, Elizabeth
    Carvajal, Richard D.
    Varghese, Anna M.
    Lacouture, Mario E.
    Ribas, Antoni
    Patel, Sapna P.
    DeCrescenzo, Gary A.
    Emery, Caroline M.
    Groover, Anna L.
    Saha, Saurabh
    Varterasian, Mary
    Welsch, Dean J.
    Hyman, David M.
    Li, Bob T.
    [J]. CANCER DISCOVERY, 2018, 8 (02) : 184 - 195
  • [9] A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
    Carducci, Michael A.
    Wang, Ding
    Habermehl, Christina
    Bodding, Matthias
    Rohdich, Felix
    Lignet, Floriane
    Duecker, Klaus
    Karpenko, Oleksandr
    Pudelko, Linda
    Gimmi, Claude
    LoRusso, Patricia
    [J]. CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1638 - 1647
  • [10] First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
    Azaro, A.
    Rodon, J.
    Herranz, M.
    Nuciforo, P.
    Prudkin, L.
    Lopez-Busto, N.
    Balandraud, S.
    Cattan, V.
    Jacquet-Bescond, A.
    Marfai, L.
    Pauly, J.
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S54
12345